Leawood, Kansas, October 8, 2026. Paradromics, a Prevail Venture Capital portfolio company, announced that its brain-computer interface has demonstrated more than four years of stable neural recording and decoding performance in a long-term animal study.
Story Highlights
- Two sheep implanted with cortical modules representative of the electrode technology in the Connexus® BCI have shown more than four years of stable neural recording and decoding performance, Paradromics announced on October 8, 2026.
- The animals remained healthy, no electrode-array migration was observed, and spike signal-to-noise ratio stayed stable in both.
- A separate study of the full platform in six sheep has shown stable spike signal-to-noise ratio for nearly two years.
Prevail Venture Capital today highlighted an announcement from Paradromics, Inc., a Prevail portfolio company, reporting a durability milestone for the company’s Connexus® brain-computer interface (BCI). According to Paradromics, two sheep implanted with cortical modules representative of the electrode technology used in Connexus have maintained stable neural recording and decoding performance for more than four years.
“This is an important proof point,” said Matt Angle, PhD, founder and CEO of Paradromics. “It has commonly been assumed that implantable BCI architectures must trade between peak performance and long-term stability. Entire companies have been based on that premise. Now we have shown that our platform, which has demonstrated the highest information transfer rates of any BCI, can also record stably for years. It’s possible to achieve both performance and longevity in one architecture.”
Paradromics reports that both animals remained healthy, that no electrode-array migration was observed, and that spike signal-to-noise ratio (SNR) — a measure of how clearly individual neuron activity can be distinguished from background noise — stayed stable throughout. A separate study of the full Connexus platform in six sheep has shown stable spike SNR for nearly two years.
“Our responsibility as a preclinical science team is to move past demos and develop rigorous internal benchmarks to ensure that we are building a platform that the clinical team can use to develop durable therapies,” said Shaoyu Qiao, PhD, VP of Neuroscience at Paradromics. “We designed the system to be stable in vivo. We used materials that we knew would last, we developed a surgical approach that avoids electrode migration, and we made the microwires that penetrate smaller than a human hair in order to reduce biological impact. We are achieving what we set out to achieve, but this is just the first four years of what we hope will be many more years of ongoing performance.”
The company frames long-term durability as a safety issue as well as a performance one. Paradromics says the milestone comes ahead of first-in-human evaluation of the system under the Connect-One Early Feasibility Study.
“I have long endorsed that a BCI has to be safe, high performance, and durable to matter clinically,” said Stephen Ryu, MD, Chief Medical Officer of Paradromics. “The field tends to focus on the first two. But as a neurosurgeon, I see durability as a safety issue. Every additional surgery is asking the patient to take on another round of risk. Ideally, no one should need repeat brain surgery because their implant wore out. Durability may be the most important factor for a technology that’s meant to be widely adopted. At Paradromics, our goal is a single implant that lasts as long as the patient needs it. Data like this shows that’s achievable.”
Read the original announcement at paradromics.com.
About Paradromics
Paradromics is a neurotechnology company developing the Connexus® Brain-Computer Interface for individuals with severe motor and speech impairments. The company’s mission is to restore communication to people who have lost the ability to speak due to conditions such as ALS, stroke, and spinal cord injury. Paradromics is headquartered in Austin, Texas. For more information, visit paradromics.com.
About Prevail Venture Capital
Prevail Venture Capital is a Leawood, Kansas venture firm investing out of a $60M Fund I across MedTech & Longevity, Defense & Security Tech, Fintech, Deep Tech, AI, and Robotics. Prevail and its affiliated entities employ more than seventy people, with an experienced operating bench supporting portfolio companies across EOS, Culture Index, finance, marketing, and BD.
Media Contact: Regan Smith · Manager of Investor Relations · venture-capital@prevailiws.com · (913) 295-9500
Safe Harbor Statement: Statements attributed to Paradromics executives and other third parties reflect the reporting and views of those sources, not Prevail Venture Capital, and may constitute forward-looking statements within the meaning of applicable securities laws. Animal study results do not predict human outcomes. Medical device development and clinical trial outcomes are subject to significant regulatory, clinical, and commercial risks and uncertainties, and cannot be assured. These statements involve known and unknown risks and other factors that may cause actual results to differ materially from those expressed or implied. Neither Prevail Venture Capital nor Paradromics undertakes any obligation to publicly update or revise any forward-looking statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Connect with Us